Abeona Therapeutics acquired ABO-801, a Phase 3-ready oral therapy candidate for eosinophilic esophagitis (EoE), from Ellodi Pharmaceuticals with a $20 million equity payment and no upfront cash. ABO-801 has FDA Orphan Drug and Fast Track designations and has undergone extensive clinical testing. Abeona also secured $30 million through a private placement with leading life sciences investors to fund development and commercialization efforts. The company plans to start a new Phase 3 study for ABO-801 in mid-2027, aiming for topline results by the end of 2028.
Abeona Therapeutics currently has a market cap of $238.46 million on Pluang as of Nov 09, 2026 18:41 WIB, with a trading volume of 1,049,743 shares. The stock price is $3.99, down 4.32% on the day. This trading activity reflects investor response following the company's recent acquisition of ABO-801 and its $30 million private placement to support further development.
